We are international
• about myeloma TEXT SIZE   
Myeloma Treatment Options

ASH 2011

The 53rd Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, California December 10-13, 2011. The webcasts taped at the meeting are reports on the current status of some of the most interesting research in myeloma. Please be aware that at the time of posting, in some cases, the interviewees are reporting on interim data from incomplete clinical trials. Therefore not all the data presented are final results, and it is possible that results will be different when the data has matured with long-term follow-up. None of this research has yet been peer-reviewed and published in a medical journal.

International Overviews
Other Proteasome Inhibitors
Other New Agents
Genetic Studies
Maintenance Therapy
Second Primary Malignancies
ASH 2011: Dr. Ocio - Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM
Enrique M Ocio, MD
University Hospital of Salamanca
Salamanca, Spain
ASH 2011: Dr. Palumbo - A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015
Antonio Palumbo, MD
University of Torino
AOU S. Giovanni Battista
Torino, Italy

ASH 2011: Dr. Palumbo - Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study
Antonio Palumbo, MD
University of Torino
AOU S. Giovanni Battista
Torino, Italy
ASH 2011: Dr. Palumbo - Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients
Antonio Palumbo, MD
University of Torino
AOU S. Giovanni Battista
Torino, Italy

ASH 2011: Dr. Popat - An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy
Rakesh Popat, MD
UCL Cancer Institute
London, United Kingdom
ASH 2011: Dr. Jakubowiak - Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
Andrzej J Jakubowiak, MD, PhD
University of Michigan
Ann Arbor, Michigan, USA

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain
ASH 2011: Dr. Mark - T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma
Tomer M Mark, MD, MSc
Weill Cornell Medical College
New York, New York, USA

ASH 2011: Dr. Lentzsch - Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study
Suzanne Lentzsch, MD, PhD
University of Pittsburgh School of Medicine and Cancer Institute
Pittsburgh, Pennsylvania, USA
ASH 2011: Dr. Lonial - A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, USA